Eagle Point Income Company Inc. (EIC)
NYSE: EIC · Real-Time Price · USD
12.72
-0.27 (-2.08%)
At close: Aug 1, 2025, 4:00 PM
12.73
+0.01 (0.08%)
After-hours: Aug 1, 2025, 7:00 PM EDT
CTI BioPharma Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for CTI BioPharma stock has a target of 17.5, which predicts a 37.58% increase from the current stock price of 12.72.
Price Target: $17.50 (+37.58%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Sep 3, 2024.
Analyst Ratings
According to 1 stock analyst, the rating for CTI BioPharma is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '24 |
|---|---|
| Strong Buy | 1 |
| Buy | 0 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B. Riley Securities | B. Riley Securities | Strong Buy Initiates $18 | Strong Buy | Initiates | $18 | +37.58% | Sep 3, 2024 |
Financial Forecast
Revenue This Year
63.72M
from 46.22M
Increased by 37.84%
Revenue Next Year
78.58M
from 63.72M
Increased by 23.33%
EPS This Year
1.62
from 1.97
Decreased by -17.52%
EPS Next Year
1.64
from 1.62
Increased by 1.25%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 |
|---|---|---|
| High | 69.9M | 89.6M |
| Avg | 63.7M | 78.6M |
| Low | 58.4M | 68.9M |
Revenue Growth
| Revenue Growth | 2025 | 2026 |
|---|---|---|
| High | 51.2% | 40.6% |
| Avg | 37.8% | 23.3% |
| Low | 26.4% | 8.1% |
EPS Forecast
| EPS | 2025 | 2026 |
|---|---|---|
| High | 1.74 | 1.79 |
| Avg | 1.62 | 1.64 |
| Low | 1.52 | 1.52 |
EPS Growth
| EPS Growth | 2025 | 2026 |
|---|---|---|
| High | -11.3% | 10.1% |
| Avg | -17.5% | 1.2% |
| Low | -22.7% | -6.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.